Charles Schwab Investment Management Inc. Has $66.79 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Charles Schwab Investment Management Inc. grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 201,046 shares of the company's stock after purchasing an additional 2,142 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.65% of Medpace worth $66,794,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Centaurus Financial Inc. grew its position in shares of Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock valued at $505,000 after purchasing an additional 29 shares during the last quarter. Schulhoff & Co. Inc. grew its position in shares of Medpace by 1.2% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after purchasing an additional 30 shares during the last quarter. Lindenwold Advisors INC grew its position in shares of Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company's stock valued at $676,000 after purchasing an additional 32 shares during the last quarter. Stephens Inc. AR lifted its stake in shares of Medpace by 4.9% in the fourth quarter. Stephens Inc. AR now owns 752 shares of the company's stock valued at $250,000 after buying an additional 35 shares during the period. Finally, M&T Bank Corp lifted its stake in shares of Medpace by 1.2% in the third quarter. M&T Bank Corp now owns 3,199 shares of the company's stock valued at $1,068,000 after buying an additional 37 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $381.44.

Remove Ads

Medpace Stock Down 3.4 %

Shares of MEDP opened at $325.87 on Wednesday. The stock has a market cap of $9.93 billion, a price-to-earnings ratio of 25.80, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The company has a 50-day moving average price of $341.06 and a two-hundred day moving average price of $342.12.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.